Table 1 Demographical and clinical characteristics of the study patients
Survivors (n = 228) | Deaths (n = 20) | P | |
|---|---|---|---|
Age (year) | 66 (52–74) | 75 (65–83) | 0.001 |
Sex (Male) | 126 (55.3 %) | 13 (65 %) | 0.400 |
Coronary heart disease | 59 (25.9 %) | 4 (20 %) | 0.563 |
Diabetes | 23 (10.1 %) | 3 (15 %) | 0.759 |
Hypertension | 74 (32.5 %) | 7 (35 %) | 0.816 |
COPD | 43 (18.9 %) | 7 (35 %) | 0.151 |
Chronic heart failure | 41 (18.0 %) | 5 (25 %) | 0.984 |
Cancer | 14 (6.1 %) | 4 (20 %) | 0.066 |
Had operation or bed rest immobilization <4 weeks | 54 (23.7 %) | 10 (50 %) | 0.010 |
T (°C) | 36.7 (36.4–37.1) | 36.6 (36.4–36.8) | 0.237 |
RR (min) | 21 (20–23) | 23 (20–25) | 0.007 |
HR (min) | 88 (80–96) | 94 (86–108) | 0.007 |
SBP (mmHg) | 124 (110–140) | 131 (121–150) | 0.023 |
BNP (pg/ml) | 209.25 (52.35–835.475) | 1709.1 (676.1–4986) | 0.000 |
LgBNP | 2.29 ± 0.85 | 3.19 ± 0.66 | 0.000 |
UCG-RVD | 70 (30.7 %) | 12 (60 %) | 0.008 |
CT-RVD | 61 (26.8 %) | 10 (50 %) | 0.027 |
sPESI | 0 (0–1) | 1 (1–2) | 0.000 |
WBC (109/L) | 8.47 ± 3.05 | 9.146 ± 3.24 | 0.348 |
NEU (109/L) | 5.70 (4.36–7.96) | 7.79 (5.58–9.15) | 0.035 |
LYM (109/L) | 1.41 ± 0.71 | 0.74 ± 0.33 | 0.000 |
Monocytes (109/L) | 0.46 (0.29–0.60) | 0.37 (0.24–0.55) | 0.285 |
HGB (g/L) | 126.145 ± 19.11 | 111.05 ± 17.61 | 0.001 |
HCT | 38.1 ± 5.49 | 33.7 ± 5.29 | 0.001 |
MCV | 91.55 (88.10–94.95) | 91.70 (89.35–93.83) | 0.823 |
RDW (fl) | 44.35 (41.6–49.0) | 47.0 (45.0–50.5) | 0.033 |
PLT (109/L) | 228.5 (182.25–298.0) | 228.5 (172.25–300.20) | 0.868 |
MPV (fl) | 9.26 ± 1.10 | 9.02 ± 1.046 | 0.346 |
PDW (fl) | 16.1 (15.83–16.40) | 16.00 (15.90–16.50) | 0.967 |
NLR | 4.43 (2.83–7.88) | 10.00 (6.13–18.49) | 0.000 |
PLR | 172.25 (125.19–284.5) | 371.94 (221.13–511.37) | 0.000 |